Pages that link to "Q34566620"
Jump to navigation
Jump to search
The following pages link to The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys (Q34566620):
Displaying 50 items.
- Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys (Q28373813) (← links)
- Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist. (Q30734343) (← links)
- Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease (Q31913332) (← links)
- Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists (Q32020572) (← links)
- Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease (Q33499111) (← links)
- The role of excitotoxicity in neurodegenerative disease: implications for therapy (Q33639170) (← links)
- The substantia nigra conveys target-dependent excitatory and inhibitory outputs from the basal ganglia to the thalamus (Q33707910) (← links)
- Functional changes of the basal ganglia circuitry in Parkinson's disease. (Q33924857) (← links)
- Remacemide: current status and clinical applications (Q34074824) (← links)
- Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation (Q34223052) (← links)
- Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases (Q34296136) (← links)
- Ion channel diseases of the central nervous system. (Q34320159) (← links)
- Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study (Q34619534) (← links)
- The pharmacological manipulation of glutamate receptors and neuroprotection (Q34768773) (← links)
- Glutamate receptors and Parkinson's disease: opportunities for intervention (Q35107721) (← links)
- Striatal glutamatergic mechanisms and extrapyramidal movement disorders (Q35165439) (← links)
- AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs. (Q35809357) (← links)
- Identification of a subunit-specific antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate/kainate receptor channels (Q36063415) (← links)
- Activation of presynaptic kainate receptors suppresses GABAergic synaptic transmission in the rat globus pallidus (Q36328049) (← links)
- Antioxidative therapeutic strategies for Parkinson's disease (Q36349448) (← links)
- A single amino acid determines the subunit-specific spider toxin block of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor channels (Q36417671) (← links)
- Glutamate receptors as therapeutic targets for Parkinson's disease (Q37585401) (← links)
- Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease (Q38056852) (← links)
- Therapeutic potential of targeting glutamate receptors in Parkinson's disease. (Q38190016) (← links)
- Advances in non-dopaminergic treatments for Parkinson's disease (Q38218083) (← links)
- Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease (Q38262418) (← links)
- AMPA receptors undergo channel arrest in the anoxic turtle cortex (Q38459255) (← links)
- Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives (Q39931409) (← links)
- Chemical signalling in the globus pallidus in parkinsonism. (Q40621104) (← links)
- Tremulous jaw movements in rats: a model of parkinsonian tremor. (Q40830468) (← links)
- Glutamate and Parkinson's disease (Q41056504) (← links)
- Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. (Q41334106) (← links)
- Dopamine/glutamate interactions in Parkinson's disease (Q41509241) (← links)
- Differential effects of bilateral dopamine depletion in neonatal and adult rats (Q41509252) (← links)
- Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease (Q41509262) (← links)
- Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action (Q41509280) (← links)
- Radiosynthesis and preliminary PET evaluation of (18)F-labeled 2-(1-(3-fluorophenyl)-2-oxo-5-(pyrimidin-2-yl)-1,2-dihydropyridin-3-yl)benzonitrile for imaging AMPA receptors (Q41634484) (← links)
- Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: A behavioral and Fos immunohistochemical study (Q41679444) (← links)
- Metabotropic glutamate receptors for Parkinson's disease therapy (Q41818450) (← links)
- The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine (Q42284740) (← links)
- Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. (Q42439060) (← links)
- Dopamine and glutamate control each other's release in the basal ganglia: a microdialysis study of the entopeduncular nucleus and substantia nigra (Q42440073) (← links)
- Rearrangement of the dendritic morphology of the neurons from prefrontal cortex and hippocampus after subthalamic lesion in Sprague-Dawley rats. (Q42449696) (← links)
- NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy- piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats (Q42449742) (← links)
- Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. (Q42468515) (← links)
- Protection against dopaminergic nigrostriatal cell death by excitatory input ablation (Q42487442) (← links)
- The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease: a quantitative autoradiographic study using [3H]MK-801, [3H]glycine, [3H]CNQX and [3H]kainate (Q42488396) (← links)
- Co-localization of AMPA-type glutamate receptor immunoreactivity in neurons of the rat subthalamic nucleus (Q43548458) (← links)
- LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats (Q43773506) (← links)
- The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals (Q44450643) (← links)